BioSpace News Archive

ReNeuron Group plc announced that Olav Hellebø, the Company’s Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9, 2019 at 3:30 p.m. BST at the Grosvenor House in London.

Jnana Therapeutics announced the appointment of Donald Nicholson, Ph.D., an accomplished scientist and executive, as chair of its Board of Directors.

Zebra Medical Vision, the deep learning imaging analytics company, announces its third patent, the latest for technology that evaluates osteoporosis risk and bone mineral density values.

Syros Pharmaceuticals announced that it has priced its concurrent underwritten public offerings of 8,667,333 shares of its common stock and accompanying Class A warrants to purchase up to 1,951,844 shares of its common stock

Endo International plc announced that one of its operating companies, Par Pharmaceutical, has begun shipping an authorized generic version of Merck’s PROVENTIL® HFA Inhalation Aerosol, 120mcg.

Gamida Cell Ltd., a leading cellular and immune therapeutics company, announced that Julian Adams, Ph.D., the company’s chief executive officer, will present an overview of the company at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019, at 10:40 a.m. ET in New York City.

The new American College of Radiology (ACR) Data Science Institute® (DSI) ACR AI-LAB™, a groundbreaking free software platform, will empower local radiologists to participate in the creation, validation and use of health care artificial intelligence (AI).

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, today announced updated data following its presentation at the American Association for Cancer Research.

After an intensive transition period started on September 4th, Olon India will start definitively all the activities the next April 1st according to the strategy of Olon S.p.A.

Filing Supported by Data Demonstrating Non-inferiority Compared to Truvada® Coupled with Bone and Renal Safety Advantages in People at Risk of Sexually Acquired HIV Infection